Novavax marked a significant financial turnaround in 2025, posting $1.12 billion in revenue—a 64.7% increase year-over-year—and turning operating income positive at $453 million after sustained losses. Central to this resurgence is its Matrix-M™ adjuvant and protein subunit vaccine platform, powering authorized vaccines like Nuvaxovid and the R21 malaria candidate, alongside lucrative licensing deals with industry majors Pfizer and Sanofi. Despite challenges including regulatory scrutiny and manufacturing complexities, Novavax’s capital structure adjustments and strategic collaborations underpin expectations of continued pipeline advancement and potential revenue expansion.